Transactions
7
Insider / Wave Life Sciences, Inc.
RA CAPITAL MANAGEMENT, L.P.
Director at Wave Life Sciences, Inc.
- Company
- Wave Life Sciences, Inc.
- Ticker
- WVE
- First filing on record
- November 14, 2025
- Latest trade on record
- October 5, 2026
- SEC filings
- EDGAR ↗
RA CAPITAL MANAGEMENT, L.P., Director at Wave Life Sciences, Inc., has disclosed 7 transactions in WVE since November 14, 2025: 5 purchases (5 open-market buys) and 0 sales, worth about $54.6M at the reported prices. The latest was filed October 7, 2026, 2 days after the trade.
Open-market buys
5
Sales
0
Avg. disclosure lag
2.3d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months RA CAPITAL MANAGEMENT, L.P. made 5 purchases worth $55M and no sales, plus 2 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
RA CAPITAL MANAGEMENT, L.P. has traded 1 stock on record; the largest by dollars is WVE.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 3 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| P | Open-market purchase | 5 | 8,773,496 | $54.6M |
| A | Grant or award | 2 | 74,700 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 6 | 4 · $54.6M | 0 |
| 2025 | 1 | 1 · $6,688 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| WVE | Other A | October 5, 2026 | October 7, 2026 | 2d | 64,000 | — | — | indirectderivative | Form 4 ↗ | |
| WVE | Other A | October 5, 2026 | October 7, 2026 | 2d | 10,700 | — | — | indirect | Form 4 ↗ | |
| WVE | Buy P | March 30, 2026 | March 30, 2026 | 0d | 971,091 | $7 | $6.3M | indirect | Form 4 ↗ | |
| WVE | Buy P | March 27, 2026 | March 30, 2026 | 3d | 2,495,623 | $6 | $16.0M | indirect | Form 4 ↗ | |
| WVE | Buy P | March 26, 2026 | March 30, 2026 | 4d | 351,224 | $6 | $2.2M | indirect | Form 4 ↗ | |
| WVE | Buy P | March 26, 2026 | March 30, 2026 | 4d | 4,954,558 | $6 | $30.0M | indirect | Form 4 ↗ | |
| WVE | Buy P | November 13, 2025 | November 14, 2025 | 1d | 1,000 | $7 | $6,688 | indirect | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 7, 2026 | Form 4 | 0001231919-26-001433 | 2 | published | EDGAR ↗ |
| March 30, 2026 | Form 4 | 0001231919-26-000297 | 4 | published | EDGAR ↗ |
| November 14, 2025 | Form 4 | 0001231919-25-000499 | 1 | published | EDGAR ↗ |
Other insiders at Wave Life Sciences, Inc.
- Francis Chris See Remarks 36 rows
- GLAXOSMITHKLINE PLC Insider 33 rows
- Moran Kyle Chief Financial Officer 19 rows
- Tan Aik Na Director 19 rows
- HENRY CHRISTIAN O Director 12 rows
- Wagner Heidi L Director 10 rows
- Rawcliffe Adrian Director 7 rows
- TAKANASHI KEN Director 5 rows
- CORRIGAN MARK Director 4 rows
- Verdine Gregory L. Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: Wave Life Sciences, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 3 | 7 | November 14, 2025 | October 7, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.